Mark Emberton, MD, FRCS, Author at Grand Rounds in Urology

Mark Emberton, MD, FRCS

University College London

London, United Kingdom

Mark Emberton, MD, FRCS, is Dean for the Faculty of Medical Sciences, and Professor of Interventional Oncology for the Division of Surgery and Interventional Science at University College London in London, England. He is also an Honorary Clinical Director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England, and UCL Partners' Pathway Director for urological oncology for London Cancer. Professor Emberton’s clinical research is aimed at improving the diagnostic and risk stratification tools and treatment strategies for prostate cancer. He specializes in the implementation of new imaging techniques, nanotechnologies, bio-engineering materials, and non-invasive treatment approaches, such as high intensity focused ultrasound and photo-dynamic therapy.

Dr. Emberton received his Bachelor’s of Medicine and of Surgery from St. Mary’s Hospital Medical School in London, England. He also received an Intercalated BSc in Psychology from Bedford College in Bedford, UK. Dr. Emberton then completed two fellowships at the Royal College of Surgeons of England in London, England. He received his Doctorate in Medicine for the University of London in London, England.

Dr. Emberton has published over 300 peer-reviewed publications and has been cited in BMJ, Lancet Oncology and European Urology. He has contributed to the development of guidelines for the management of prostate cancer and lower urinary tract symptoms, published by the International Society of Geriatric Oncology and the European Association of Urology. Dr. Emberton is also involved in teaching within UCL and the London and South East Urological Training scheme. He is also a member of various urological and medical organizations (the American Association of GenitoUrinary Surgeons, the British Association of Urological Surgeons, the European Association of Urology). He is Founding Pioneer of the charity Prostate Cancer UK, and a founding partner of London Urology Associates.

Talks by Mark Emberton, MD, FRCS

Case Discussions: Surveillance and Recurrence in Focal Therapy

Arvin K. George, MD, Mark Emberton, MD, FRCS, Gopal N. Gupta, MD, FACS and Samir S. Taneja, MD | Apr 2026

Expert panelists analyze PSA patterns, imaging, and biopsy results in complex post-ablation surveillance cases.

Lesional Management in Early Prostate Cancer

Mark Emberton, MD, FRCS | Mar 2026

Dr. Mark Emberton explains how MRI-defined lesions and lesion-directed biopsy reshape risk stratification and management in early prostate cancer.

Panel Discussion: MRI and PSMA Discordance

Abhinav Sidana, MD, MPH, FACS, Steven P. Rowe, MD, PhD, Mark Emberton, MD, FRCS, Arvin K. George, MD and Sadhna M. Verma, MD, MBA, FSAR | Feb 2026

Experts discuss MRI and PSMA discordance, demonstrating how combined imaging enhances lesion evaluation.

Changing Relationship between Active Surveillance and Focal Therapy

Mark Emberton, MD, FRCS | Jul 2025

Mark Emberton, MD, discusses the evolving roles of active surveillance and focal therapy in managing prostate cancer.

MRI-Based Prostate Cancer Screening in an Era of MCEDs

Mark Emberton, MD, FRCS | Nov 2024

Mark Emberton, MD, FRCS, discusses advancements in prostate cancer screening, emphasizing the limitations of current methods and the potential of innovative approaches.

In this 9-minute presentation, Emberton discusses emerging technologies, such as polygenic risk scoring and advanced biomarkers, that hold promise for enriching high-risk populations. Imaging, particularly bi-parametric MRI, is presented as a leading tool.

Emerton introduces TRANSFORM, a prostate cancer screening study funded by Prostate Cancer UK and the NHS. Developed through a collaborative, multidisciplinary approach, the study incorporates randomization to minimize bias and contamination. Adaptive trial design ensures underperforming methods are replaced, and novel tests can be incorporated as they emerge. Emerton expresses optimism that this innovative approach will shape the future of prostate cancer screening, addressing equity, efficiency, and scientific rigor.